Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5,988 INR | -1.14% | -4.81% | +3.23% |
08/05 | Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading | MT |
08/05 | Indian Equities Settle Flat on Wednesday, Dragged by Banks, FMCG Stocks | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 3.37 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.23% | 12.08B | - | ||
+32.95% | 698B | C+ | ||
+26.51% | 568B | B | ||
-4.97% | 358B | C+ | ||
+18.83% | 328B | B- | ||
+3.54% | 283B | C+ | ||
+15.70% | 238B | B+ | ||
+6.68% | 203B | B- | ||
-9.08% | 198B | A+ | ||
+6.70% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DRREDDY Stock
- DRREDDY Stock
- Ratings Dr. Reddy's Laboratories Limited